Song Y.,Qingdao University |
Zhang H.,Qingdao University |
Song S.,No 307 Hospital Of Military Medical Science Academy Of The Pla |
Jiang Z.,No 307 Hospital Of Military Medical Science Academy Of The Pla
Chinese Journal of Clinical Oncology | Year: 2011
Objective: To discuss the expression and location of the transcription factor Fra-1 in benign and malignant human breast tissues. Methods: Fra-1 expression was investigated immunohistochemically in neoplastic breast diseases ranging from benign fibroadenomas to very aggressive undifferentiated carcinomas. The correlation between Fra-1 expression and other indicators of breast carcinoma prognosis (ER, PR, and ErbB2 receptors) were analyzed. Results: The nuclei of all neoplastic breast tissue cells, both in benign and malignant breast tissues, were immunoreactive to anti-Fra-1 antibodies. In 85% of the benign tumors (17/20), the immunoreactivity of the anti-Fra-1 antibodies was exclusively restricted to the nuclei. In three cases (3/20, 15%), focal unequivocal cytoplasmic staining was also observed. Strong positive nuclear staining for Fra-1 was easily seen in all types of breast carcinomas. However, concomitant nuclear-cytoplasmic immunoreactivity was observed in all types of breast carcinomas. A clear shift in Fra-1 immunoreactivity, from an exclusively nuclear to a simultaneous nuclear and cytoplasmic localization, was observed in 90.2% (37/41) of breast carcinomas. No inverse relationship was observed between Fra-1 and the ER and PR protein levels in the malignant tumors. The relative Fra-1 expression level was not correlated with ErbB2 expression. Conclusion: The overall expression, pattern, and intensity of the Fra-1 protein were correlated with breast oncogenesis. Fra-1 overexpression, leading to persistently high cytoplasmic accumulation, may play a role in breast carcinogenesis.
Zhong K.,No 307 Hospital Of Military Medical Science Academy Of The Pla |
Su H.,No 307 Hospital Of Military Medical Science Academy Of The Pla |
Xiao X.,No 307 Hospital Of Military Medical Science Academy Of The Pla |
Liu J.,No 307 Hospital Of Military Medical Science Academy Of The Pla |
And 5 more authors.
Chinese Journal of Clinical Oncology | Year: 2014
Objective: The effect and side effect of the dose-adjusted EPOCH regimen were evaluated perspectively for the preliminarily diagnosed angioimmunoblastic T-cell lymphoma.Methods: Nine cases of untreated angioimmunoblastic T-cell lymphoma were diagnosed and enrolled in our department from September 2008 to September 2012. All patients received dose-adjusted EPOCH regimen as first-line chemotherapy.Results: The median age of 9 patients was 54 years. The male-to-female ratio was 2:1. About 88.9% of all patients were at Ann Arbor stage III/IV, and 77.8% presented with B symptoms. Anemia was found in 66.7% of 9 patients, and lactate dehydrogenase elevated in 55.6% of patients. After an average of 4.7 cycles of chemotherapy of dose-adjusted EPOCH regimen, the complete remission rate was 22.2%, and the total response rate was 66.7%. With a median follow-up of 20 months, the 4-year progression-free survival rate was 11.1%, and the overall survival rate was 33.3%. The median survival time was 19 months. The most common adverse events of EPOCH chemotherapy were hematologic toxicity. Grades 3-4 neutropenia and thrombocytopenia were reported in 77.8% and 33.3% of patients. Febrile neutropenia was observed in 44.4% of patients. Non-treatment-related mortality was also noted.Conclusion: The results of our research showed no clear benefit of treating preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen. The main adverse events were hematologic toxicity and could be tolerated.